-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-521349-25-00
5
2025-12-09
Macular neovascularization secondary to age-related macular degenerati
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2025-520612-34-00
5
2025-11-28
Agitation Associated with
Alzheimer’s Disease
-
2024-520384-14-00
4
2025-11-20
Centre-involved diabetic macular edema
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2025-520478-20-00
5
2025-11-05
Thromboembolic disease
-
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2025-520564-17-00
5
2025-10-16
Hidradenitis suppurativa (HS)
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)